Are central venous lactate and arterial lactate interchangeable? A human retrospective study.

BACKGROUND: In critically ill patients, arterial blood lactate concentration (Lact(a)) and Lact(a) clearance are used for the diagnosis of shock, for prognosis assessment, and to guide therapy. In recent years, central venous oxygen saturation (ScvO(2)), a surrogate for mixed venous blood saturation, either measured by fiberoptic catheters or from central venous blood samples, was used in shock to estimate the global balance between oxygen delivery and consumption. When central venous blood is drawn for ScvO(2) measurement, it also could be used to measure central venous lactate concentration (Lact(cv)). In this study, we evaluated the utility of Lact(cv) and Lact(cv) clearance as predictors of Lact(a) and Lact(a) clearance, respectively, in critically ill patients. METHODS: This retrospective study was performed in an intensive care unit of a regional and teaching hospital. Using the electronic registry of our blood gas analyzer from March 2007 to December 2009, we identified patients with circulatory or respiratory failure who had pairs of Lact(cv) and Lact(a) obtained within a 30-minute interval. To assess the utility of Lact(cv) as a predictor of Lact(a) above 2 and 4 mmol/L, we calculated the area under receiver operating characteristic curves (AUCs) for these thresholds. We also calculated AUC of Lact(cv) clearance to detect a Lact(a) clearance <10% or >10%. RESULTS: Six hundred seventy-three Lact(cv)/Lact(a) pairs in 188 patients were analyzed. AUC of Lact(cv) to predict a Lact(a) above 2 and 4 mmol/L was 0.98 (95% confidence interval: 0.97-0.99) and 0.98 (95% confidence interval: 0.96-0.99), respectively. Lact(cv) with the cutoff value of 2 mmol/L can predict a Lact(a) above 2 mmol/L with sensitivity >92% and specificity >90%. AUC for Lact(cv) clearance to detect a Lact(a) clearance <10% or >10% was 0.93 or 0.94, respectively. CONCLUSION: Lact(cv) and Lact(a) collected within a 30-minute range are interchangeable for clinical practice.

[Hemorrhagic cystitis due to adenovirus in a renal transplant recipient: the first reported case in black Africa in a setting of a very beginning of a kidney transplantation program and review of the literature]. / Cystite hémorragique à adénovirus chez le transplanté rénal: à propos d'un premier cas en Afrique noire survenu dans un tout débutant programme de greffe rénale et revue de la littérature.

Viral infections are an important complication of transplantation. Polyomavirus are the commonest viruses that infect the renal allograft. Herpes virus nephropathy has also been described. In the past 15 years, adenovirus nephritis has emerged as a potentially life-threatening disease in renal transplant patients in developed countries. Most of the papers devoted to adenovirus nephritis are reported cases. The fate of such patients in resources-limited countries is not known. Herein, we describe the clinical, biological and prognostic findings of a black African transplanted patient with adenoviral hemorrhagic cystitis. This case is the very first of its kind reported in black Africa in a setting of a start of a renal transplantation pilot project. The patient is a 54-year-old man admitted at the nephrology service for gross haematuria and fever occurred 1 month after kidney transplantation. The diagnosis of adenoviral hemorrhagic cystitis has been suspected because the patient has displayed recurrent conjunctivitis and gastroenteritis well before transplantation, which was then confirmed by the real-time polymerase chain reaction performed on the blood. Conservatory measures associated with immunosuppression reduction have permitted the discontinuation of haematuria. This case has been discussed in regard of the epidemiology, the diagnosis, the treatment, the evolution and the prognosis of the adenoviral infection in the renal transplant patient. A review of the literature has been performed subsequently.